Flourish Research is where clinical trials thrive.
Flourish Philadelphia started as Keystone Clinical Studies in 2003. Our Founder, Cherian Verghese, MD has a background in academic psychiatric research, teaching and clinical care. Our expert team has worked on over 175 clinical trials which led to the approval of medications for 13 neuro-psychiatric conditions. We are the premier trial site in the Greater Philadelphia region and enjoy a reputation for clinical care and data integrity with our patients, community organizations, Sponsors and CROs. A special strength is in Alzheimer’s disease, where we have studies targeting multiple pathological mechanisms, at many stages of the illness, with industry-leading recruitment and retention, especially in minority populations.
At Flourish Research, we strive toward excellence. In clinical trials and healthcare, excellence means everyone deserves the best care, regardless of their race, color, gender identity, religion, ethnicity, physical abilities, age, sexual orientation, or veteran status. We embrace employees, customers, and patients from all underrepresented groups to help make this vision a reality.
Flourish Research is driven by a diverse and inclusive community of passionate people who are committed to improving the quality of life of communities around the world. Flourish is committed to a safe work environment where all employees, customers, and patients are included, and treated with dignity and respect.
Flourish strives to build an organization that attracts and leverages diversity in our staff, which reflects the diversity of our local communities. We promote education, acceptance, and inclusion because there is beauty in diversity. The more diversity we have in our team, the more unique perspectives, and ideas we share, and the better prepared we are to serve our communities. WE SEE YOU. WE ARE YOU. WE EMBRACE YOU. WE CELEBRATE YOU!
Stay current with the latest clinical trial news and learn how Flourish Research is supporting the advancement of life-changing therapeutics.